R-Oxybutynin HCl Polymorph Control for Stable OSA Formulations

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing oxybutynin formulations lack stability and efficacy due to variations in crystalline forms, which affect their pharmacokinetic properties and therapeutic outcomes.

Innovation Solution

Development of three distinct crystalline forms (A, B, and C) of (R)-oxybutynin hydrochloride, characterized by unique XRPD patterns and thermal stability, to enhance stability and efficacy.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional oxybutynin formulations are used, then the drug can be administered, but the formulations lack stability and efficacy due to variations in crystalline forms

Engineering Contradiction:

ImprovestabilityVSAvoidcrystalline form consistency

Core Design Contradiction:

ReliabilityVSStability of the object's composition

Solution Approach 1:

The patent applies parameter changes by controlling specific crystallization conditions including temperature (20-25°C), pH (3.5-4.5), and solvent composition (acetone/water ratio) to obtain a specific polymorphic form of oxybutynin hydrochloride with improved stability and efficacy. This resolves the contradiction by standardizing the crystalline structure through controlled parameter variations during synthesis.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If conventional oxybutynin formulations are used, then the drug can be administered, but the formulations lack consistent pharmacokinetic properties due to variations in crystalline forms

Engineering Contradiction:

ImproveefficacyVSAvoidpharmacokinetic consistency

Core Design Contradiction:

ReliabilityVSManufacturing precision

Solution Approach 1:

The patent controls crystallization parameters including temperature (20-25°C), pH (3.5-4.5), and solvent composition to produce a consistent polymorphic form, ensuring uniform pharmacokinetic properties across batches. This resolves the contradiction by establishing precise manufacturing parameters that guarantee both efficacy and pharmacokinetic consistency.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent replaces conventional synthesis methods with a controlled crystallization process that uses chemical parameters (pH, solvent ratio, temperature) rather than mechanical processing to achieve consistent crystalline forms. This substitution ensures reproducible pharmacokinetic properties by relying on thermodynamic control rather than mechanical variability.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

3Adaptability or versatility

If multiple crystalline forms are present, then the drug has versatility in formulation, but the variations in crystalline forms affect therapeutic outcomes

Engineering Contradiction:

Improveformulation flexibilityVSAvoidtherapeutic outcome consistency

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent selects and controls specific crystallization parameters (temperature, pH, solvent composition) to obtain a predetermined polymorphic form with consistent therapeutic properties. This resolves the contradiction by using parameter control to achieve formulation flexibility while ensuring therapeutic outcome consistency through reproducible crystalline structure.

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The crystalline forms provide improved stability and therapeutic efficacy, ensuring consistent pharmacokinetic properties and enhanced drug delivery.

Implementation Method 1

characterized by unique XRPD patterns

Methodology Applied

Scientific EffectX-ray powder diffraction: X-Ray

Implementation Method 2

thermal stability

Methodology Applied

Scientific EffectDifferential scanning calorimetry: Calorimetry

Data Source

PatentUS20260022091A1Polymorphic forms of (r)-oxybutynin hydrochloride

Publication Date: 2026.01.22 APNIMED INC (DELAWARE)

AI summary

Polymorphic forms of (R)-oxybutynin HCl, including three crystalline forms, are prepared and characterized. Uses of the various polymorphic forms of (R)-oxybutynin HCl for Obstructive Sleep Apnea (OSA) treatment are also disclosed.